The nasal vacine to treat Covid-19 infection is now developed, as per the reports of NIH. Notably, the director for the National Institutes of Health declared that by this week the nasal spray being developed to treat COVID-19.
In a statement, Dr. Francis Collins, the NIH Director mentioned, “I’m pleased to share progress in the development of a specially engineered therapeutic antibody that could be delivered through a nasal spray. Preclinical studies also suggest it may work even better than existing antibody treatments to fight COVID-19, especially now that new SARS-CoV-2 ‘variants of concern’ have become increasingly prevalent.”
The announcement of the director was posted as a blog on the official website of NIH. In addition, the follows and researches of the Chinese experts and The University of Texas was also available there, in order to support it.
Significanty, the nasal spray developed by the NIH is full of Covid-19 antibodies. These antibodies basically enter in the main spots from where the infection prevails, such as nasal cavities. Further, it becomes tougher for the virus to proceed to the other spots and thus the infection can be stopped from spreading.